Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib

Ruxolitinib is widely in use for treatment of myeloproliferative disorders. It causes inhibition of the Janus kinase (JAK) signal transducer and activation of transcription (STAT) pathway, which plays a key role in the underlying pathophysiology of myeloproliferative diseases. We describe a case of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Case Rep Hematol
Autors principals: Abidi, Maheen Z., Haque, Javeria, Varma, Parvathi, Olteanu, Horatiu, Guru Murthy, Guru Subramanian, Dhakal, Binod, Hari, Parameswaran
Format: Artigo
Idioma:Inglês
Publicat: Hindawi Publishing Corporation 2016
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5097796/
https://ncbi.nlm.nih.gov/pubmed/27843657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/2389038
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars